A Phase 3 interventional study of lisdexamfetamine and Placebo control in Binge Eating Disorder, sponsored by Lindner Center of HOPE. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-15.
Sponsored by Lindner Center of HOPE · Phase 3, Interventional, and Treatment
The specific aim of this study is to examine the efficacy and safety of lisdexamfetamine compared with placebo in outpatients with binge eating disorder
319 studies on the registry are indexed under Bulimia; 53 are open to participants now.
This study's enrollment of 50 is below the median of 61 across 249 interventional studies indexed under Bulimia.
Browse Bulimia studies →Lindner Center of HOPE is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
drug
Drug: lisdexamfetamine
Placebo comparator
Drug: Placebo control
oral; 20-70mg/day
20-70mg; oral
frequency of binge eating episode
frequency of binge eating episode
Time frame: 12 weeks
This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lindner Center of HOPE